Who
Frederick M. Hudson
Director
Company insider
Files Form 4 as: Director, Supernus Pharmaceuticals; Director, scPharmaceuticals; Director, Aradigm; Director, Vicor Technologies.
In numbers
- Trades disclosed
- 89
- Buys
- 1
- Sells
- 5
- Bought
- $25K
- Sold
- $1.5M
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 25 Jun 2008
- Last trade
- 12 Mar 2026
- Last filed
- 16 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Mar 2026filed 16 Mar 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $272K5,369 at $50.61 | filing |
| 12 Mar 2026filed 16 Mar 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $272K5,369 at $50.61 | filing |
| 24 Feb 2026filed 25 Feb 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —4,475 at $0.00 | filing |
| 24 Feb 2026filed 25 Feb 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —4,475 at $0.00 | filing |
| 24 Feb 2026filed 25 Feb 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —4,475 at $0.00 | filing |
| 24 Feb 2026filed 25 Feb 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —4,475 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —2,989 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —4,977 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —2,989 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —4,977 at $0.00 | filing |
| 9 Jan 2026filed 12 Jan 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $195K15,000 at $12.98 | filing |
| 9 Jan 2026filed 12 Jan 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —15,000 at $0.00 | filing |
| 9 Jan 2026filed 12 Jan 2026 | SUPN Supernus Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —15,000 at $0.00 | filing |
| 9 Jan 2026filed 12 Jan 2026 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $195K15,000 at $12.98 | filing |
| 7 Oct 2025filed 7 Oct 2025 | scPharmaceuticalsoption or derivative | SEC FORM 4 Code D | —30,000 at $0.00 | filing |
| 7 Oct 2025filed 7 Oct 2025 | scPharmaceuticalsoption or derivative | SEC FORM 4 Code D | —19,750 at $0.00 | filing |
| 7 Oct 2025filed 7 Oct 2025 | scPharmaceuticalsoption or derivative | SEC FORM 4 Code D | —16,300 at $0.00 | filing |
| 7 Oct 2025filed 7 Oct 2025 | scPharmaceuticalsoption or derivative | SEC FORM 4 Code D | —6,124 at $0.00 | filing |
| 14 Aug 2025filed 18 Aug 2025 | SUPN Supernus PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $315K7,457 at $42.26 | filing |
| 3 Jun 2025filed 5 Jun 2025 | scPharmaceuticalsoption or derivative | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
News
Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026SUPN · manilatimes.net · 19 Oct 2026Supernus Pharmaceuticals (NASDAQ:SUPN) vs. Kiora Pharmaceuticals (NASDAQ:KPRX) Critical SurveySUPN · tickerreport.com · 11 Oct 2026Shineco (NASDAQ:SISI) vs. Supernus Pharmaceuticals (NASDAQ:SUPN) Financial AnalysisSUPN · dailypolitical.com · 8 Oct 2026
0 headlines in the last 90 days name Frederick M. Hudson; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.